This site is intended for healthcare professionals residing in Canada.

Visit Pfizer AcademySearch

Menu

Close

Sign InLog Out
  • EN
ProductsTherapy AreasExplore ContentExplore
ContentGo to Explore ContentEventsMaterialsVideosPatient SupportContact
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Français

Menu

Close

Home

Recommendations

SOGC Recommendations

NACI Recommendations

CIQ Recommendations

About RSV

About RSV

Infants at Risk

Individuals ≥ 60 Years of Age

About ABRYSVO

Reconstitution and Storage

Dosing and Administration

Mechanism of Action

Efficacy and Safety Profiles

Clinical Trials

MATISSE Study Design

MATISSE Data

MATISSE Safety Profile

RENOIR Study Design

RENOIR Data

RENOIR Safety Profile

More

Coverage Information

Patient Profiles

FAQ

Resources

Product MonographSafety Information
Pfizer Respiratory Vaccine Portfolio
Public funding and private
coverage informationPublic funding and private coverage informationPublic funding

Provincial and federal funding are now available in select provinces.

Restrictions may apply. Refer to your respective provincial and federal listings for full coverage details and restrictions.1*†Private insurance

The cost of ABRYSVO may be covered by your patients’ private insurance. They can contact their insurance provider and provide the drug identification number (02544040) to find out.

SOGC: Society of Obstetricians and Gynaecologists of Canada; NACI: National Advisory Committee on Immunization; CIQ: Comité sur l’immunisation du Québec
*Funding for older adults is available in Ontario, Quebec, Alberta, Manitoba, New Brunswick, Nova Scotia, and Yukon and covered by Veterans Affairs Canada as of November 2024. 
†Funding for pregnant individuals is available in Ontario and covered on Veterans Affairs Canada as of November 2024. Reference:Data on file. Pfizer Canada ULC. November 26, 2024.MoreEfficacy and Safety Profiles

Investigate ABRYSVO’s efficacy and safety profiles in infants and individuals ≥ 60 years of age.

Recommendations

Learn more about SOGC, NACI, and CIQ recommendations.

PP-A1G-CAN-0117-EN

To report an adverse event, please call 1-866-723-7111

PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign in or RegisterSign inRegisterAccountSign Out

© Pfizer Canada ULC 2024. All rights reserved. The information is intended only for healthcare professionals resident in Canada. ®Pfizer Inc., used under license.

PP-UNP-CAN-0145-EN
You are now leaving Pfizerpro.ca website
Links to other sites are provided as a convenience to the viewer, and should not be taken as an endorsement of the sites or an association with their owners. Pfizer Canada accepts no responsibility for the content of linked sites.
You are now leaving the PfizerPro Portal.
You are about to view resources made available by Pfizer Academy. 
These resources include learning programs and upcoming events. By selecting Go to link below, you acknowledge and certify that you are a Canadian Healthcare Professional.
PP-UNP-CAN-0013 EN
Are you a resident of Quebec?